A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions

Faculty

Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:yhandelsman@pacbell.net
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.

Copyright © 2010 Elsevier Inc.

A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions

Faculty

Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:yhandelsman@pacbell.net
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.

Copyright © 2010 Elsevier Inc.

A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions

Faculty

Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:yhandelsman@pacbell.net
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.

Copyright © 2010 Elsevier Inc.

A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.

“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.

Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”

The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”

Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:

• Following the costs and intricacies of technical implementation; 
• Getting local physician buy-in;
• Creating a multidisciplinary approach that includes nurses and pharmacists; and
• Putting periodic reviews in place to measure quality metrics.

“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”

A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.

“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.

Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”

The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”

Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:

• Following the costs and intricacies of technical implementation; 
• Getting local physician buy-in;
• Creating a multidisciplinary approach that includes nurses and pharmacists; and
• Putting periodic reviews in place to measure quality metrics.

“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”

A new study questioning the efficacy of telemedicine in reducing length of stay (LOS) and improving patient care in the ICU is further proof that remote patient care only works when there is a strong support structure behind it, according to a former SHM president.

“The studies in the past have not shown that just because you have an intensivist available that you are going to get a lot of bang for the buck. You need to have a real process. … If you don’t implement something properly, you can’t expect to get results,” says Mary Jo Gorman, MD, MBA, FHM, former SHM president and CEO of St. Louis-based Advanced ICU Care, which provides intensivists to community hospitals using telemedicine.

Investigators at the University of Texas Health Science Center at Houston reviewed some 4,000 patients in six ICUs at five hospitals in a large U.S. healthcare system by measuring outcomes before and after implementation of a “tele-ICU” from 2003 to 2006. No statistically significant impacts were seen in mortality rates, complications, or LOS (JAMA. 2009;302[24]:2671-2678). Conversely, an accompanying editorial in the Journal of the American Medical Association argued that “tele-ICU is a potentially valuable change in ICU care, but its complexity means that ‘tele-ICU improves care’ is not a testable hypothesis.”

The use of off-site intensivists to monitor patients has been used in recent years to address the shortage of ICU physicians. Still, the study team argues that “there are few data in the peer-reviewed literature evaluating its effect on morbidity and mortality.”

Dr. Gorman suggests that HM groups looking to partner with telemedicine providers consider the importance of:

• Following the costs and intricacies of technical implementation; 
• Getting local physician buy-in;
• Creating a multidisciplinary approach that includes nurses and pharmacists; and
• Putting periodic reviews in place to measure quality metrics.

“The tool is not the problem,” Dr. Gorman adds. “It’s how do you implement the tool.”

Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?

Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.

Study design: Prospective interventional cohort study.

Setting: Adult, urban, academic ED with an annual census of approximately 89,000.

Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.

Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.

Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.

Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.

Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University

For more HM-related literature reviews, visit our Web site.

Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?

Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.

Study design: Prospective interventional cohort study.

Setting: Adult, urban, academic ED with an annual census of approximately 89,000.

Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.

Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.

Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.

Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.

Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University

For more HM-related literature reviews, visit our Web site.

Clinical question: What are the efficacy and safety of a simplified “1+1” pain protocol using 1-mg IV hydromorphone followed by an optional repeat dose at patient request 15 minutes later in patients with acute pain?

Background: ED patients receive inadequate treatment of pain. Previously studied protocols utilized weight-based dosing, complex pain scales, and frequent nurse contact to assess and treat pain, making them less useful in a busy ED. A 2-mg single dose hydromorphone protocol provided pain relief, but was associated with oxygen desaturation.

Study design: Prospective interventional cohort study.

Setting: Adult, urban, academic ED with an annual census of approximately 89,000.

Synopsis: Participants included 223 ED patients ages 21 to 64 years old presenting with acute pain (<7 days duration) of sufficient severity to warrant use of IV opioids. Notable exclusion criteria included use of opioids within the past seven days, history of chronic pain, room air saturation <95%, systolic blood pressure <90 mm/Hg, or contraindication to hydromorphone; thus, findings are applicable to a limited set of ED patients presenting with acute pain. The hydromorphone protocol achieved patient expectations of pain relief (defined by decision to forgo additional opioid medication) in 77% of patients within 15 minutes and 96% of patients within one hour. 5% of patients dropped their oxygen saturations to <95%, but all increased promptly with 4L nasal cannula. Only 1% of patients dropped their respiratory rate to <12 breaths/minute and systolic blood pressure to <100 mm/Hg; none required naloxone use.

Limitations include lack of comparison group, unblinded design, and findings from a single urban center (in which participants were 60% Hispanic, 29% black, and 65% female). While there were no serious adverse events, the sample size is not large enough to identify rare events.

Bottom line: In nonelderly adult ED patients without a history of chronic pain or recent opioids, a pain protocol of 1-mg IV hydromorphone repeated in 15 minutes if needed is effective and safe, assuming typical ED monitoring for hypoxia and respiratory depression.

Citation: Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the “1+1” protocol. Ann Emerg Med. 2009;54(2):221-225.

Reviewed for TH eWire by Bhaskar Arora, MD, Thomas Barrett, MD, MCR, FHM, Honora Englander, MD, Stephanie Halvorson, MD, Alan J. Hunter, MD, David Kagen, MD, Blake Lesselroth, MD, MBI, Portland Veterans Affairs Medical Center and Division of Hospital Medicine, Oregon Health & Science University

For more HM-related literature reviews, visit our Web site.

A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information

Faculty/Faculty Disclosure

Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.

A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information

Faculty/Faculty Disclosure

Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.

A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.

•Topics
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information

Faculty/Faculty Disclosure

Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.

Practical Bits: Quick and Practical Diagnostic Tools

Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.

Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.

Practical Bits: Quick and Practical Diagnostic Tools

Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.

Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.

Practical Bits: Quick and Practical Diagnostic Tools

Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.

Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools